Non-Covalent BTK Inhibitors in the Treatment of CLL: Nemtabrutinib

News
Video

Dr Seema Ali Bhat continues the conversation on non-covalent BTK inhibitors in CLL treatment with a look at nemtabrutinib and data from the BELLWAVE-001 study.

Recent Videos
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Treatment with AML depends on a variety of factors, including stage of treatment, transplant eligibility, and mutational status.
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Related Content
An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.

Indirect Comparison Favors Zanubrutinib vs Venetoclax Combo in CLL/SLL

Russ Conroy
September 26th 2025
Article

An indirect comparison supports continuous therapy with zanubrutinib as a valuable treatment option in treatment-naïve CLL or SLL.

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
May 29th 2019
Podcast

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Tim Cortese
September 11th 2025
Article

Ziftomenib yielded a median overall survival of 16.4 months in responders with NPM1-mutant AML who received ziftomenib in the phase 1b/2 KOMET-001 trial.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Chronic myeloid leukemia was once known as a deadly disease, renowned for its difficulty to treat.

Recapping A Quarter Decade of Chronic Myeloid Leukemia Therapy

Tim Cortese
September 2nd 2025
Article

Jorge Cortes, MD, believes that, despite the rapid improvements made in CML treatment, there is always more to be done to help patients.

The AML Epigenomic Risk model used 946 AML-only peripheral blood or bone marrow samples at diagnosis.

AI Prognostic Tool Confirms Concordance Through Epigenomic Signatures in AML

Tim Cortese
August 26th 2025
Article

Both experimental models significantly improved upon historical clinical risk trial groups for patients with acute myeloid leukemia.